p21-Mediated Regulation of IL-6 and MMP-1 in RA
p21-Mediated Regulation of IL-6 and MMP-1 in RA
批准号:
6891933
负责人:
Harris R Perlman
金额:
$28.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-07 至 2008-04-30
关键词:
AP1 proteinAdenoviridaecell growth regulationcell proliferationclinical researchcollagenasefibroblastsfunctional /structural genomicsgene expressiongenetic regulationhuman tissueinfectious arthritisinterleukin 6jointslaboratory mouseoncoprotein p21protein structure functionrheumatoid arthritistransfection /expression vectoryeast two hybrid system
中文摘要
描述(由申请人提供):风湿性关节炎(RA)是一种慢性炎症性和破坏性关节病,可导致发病率和死亡率增加。构成滑膜衬里(滑膜成纤维细胞)的成纤维细胞是负责RA发病机制的主要细胞之一,滑膜衬里是与软骨和骨直接接触的薄膜。在RA中,滑膜成纤维细胞数量增加并产生促炎细胞因子和基质金属蛋白酶(MMP),其促进炎症和关节破坏。我们最近发现了细胞周期抑制剂p21在RA中的新作用,即p21不仅阻断细胞周期进程,还减少IL-6和MMP-1的合成。与骨关节炎滑膜成纤维细胞相比,RA中p21表达降低。p21的恢复阻断细胞周期进程,抑制RA中IL-6和MMP-1的合成,但在非RA滑膜成纤维细胞中没有。此外,恢复的p21减弱AP-1的DNA结合活性,AP-1是一种在RA期间增加的转录因子,并且是IL-6和MMP-1的已知诱导剂。与野生型细胞相比,p21缺陷型滑膜成纤维细胞表现出IL-6分泌增加100倍,IL-6和MMP-3 mRNA积累显著增加,以及AP-1 DNA结合活性增强。与Rb过表达(也诱导细胞周期停滞)相反,p21缺陷滑膜成纤维细胞中p21的恢复使IL-6和MMP-3恢复至野生型水平。基于我们的数据,我们假设p21通过抑制AP-1通路抑制IL-6和MMP-1在正常关节中的转录。在RA关节中,p21通路有缺陷,导致滑膜成纤维细胞增殖和IL-6和MMP-1合成增加。因此,RA可以通过恢复p21通路来治疗。
英文摘要
DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a chronic inflammatory and destructive arthropathy that results in increased morbidity and mortality. The fibroblasts that comprise the synovial lining (synovial fibroblasts), a thin membrane in direct contact with cartilage and bone, are one of the principal cells responsible for the pathogenesis of RA. In RA, the synovial fibroblasts increase in number and produce pro-inflammatory cytokines and matrix-metalloproteinases (MMPs) that promote inflammation and joint destruction. We recently discovered a novel role for the cell cycle inhibitor p21 in RA, namely that p21 not only blocks cell cycle progression, it also reduces the synthesis of IL-6 and MMP-1. p21 expression is reduced in RA compared to osteoarthritis synovial fibroblasts. Restoration of p21 blocks cell cycle progression and suppresses IL-6 and MMP-1 synthesis in RA but not in non-RA synovial fibroblasts. Additionally, restored p21 attenuates the DNA binding activity of AP-1, a transcription factor that is increased during RA and is a known inducer of IL-6 and MMP-1. p21-deficient synovial flbroblasts exhibit a 100-fold increase in IL-6 secretion, a marked increase in IL-6 and MMP-3 mRNA accumulation, and enhanced AP-1 DNA binding activity compared to wild-type cells. In contrast to Rb overexpression, which also induces cell cycle arrest, restoration of p21 in p21-deficient synovial fibroblasts returned IL-6 and MMP-3 to wild-type levels. Based on our data, we hypothesize that p21 suppresses IL-6 and MMP-1 transcription in the normal joint through the inhibition of the AP-1 pathway. In the RA joint, the p21 pathway is defective, resulting in proliferation of synovial fibroblasts and increased synthesis of IL-6 and MMP-1. Accordingly, RA may be treatable by restoring the p21 pathway.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Macrophage Heterogeneity in Rheumatoid Arthritis
-
批准号:10392246
-
项目类别:
-
资助金额:$69.46万
-
财政年份:2022
-
负责人:Harris R Perlman
-
依托单位:
Macrophage Heterogeneity in Rheumatoid Arthritis
-
批准号:10609468
-
项目类别:
-
资助金额:$69.47万
-
财政年份:2022
-
负责人:Harris R Perlman
-
依托单位:
Synovial Macrophage Transcriptional Signatures for Predicting Therapeutic Efficacy
-
批准号:10679089
-
项目类别:
-
资助金额:$57.91万
-
财政年份:2019
-
负责人:Harris R Perlman
-
依托单位:
Synovial Macrophage Transcriptional Signatures for Predicting Therapeutic Efficacy
-
批准号:10460247
-
项目类别:
-
资助金额:$57.09万
-
财政年份:2019
-
负责人:Harris R Perlman
-
依托单位:
Transcriptional Signature of Macrophages in SSc
-
批准号:10005890
-
项目类别:
-
资助金额:$17.38万
-
财政年份:2019
-
负责人:Harris R Perlman
-
依托单位:
Synovial Macrophage Transcriptional Signatures for Predicting Therapeutic Efficacy
-
批准号:9766023
-
项目类别:
-
资助金额:$63.65万
-
财政年份:2019
-
负责人:Harris R Perlman
-
依托单位:
Synovial Macrophage Transcriptional Signatures for Predicting Therapeutic Efficacy
-
批准号:10020786
-
项目类别:
-
资助金额:$60.02万
-
财政年份:2019
-
负责人:Harris R Perlman
-
依托单位:
Synovial Macrophage Transcriptional Signatures for Predicting Therapeutic Efficacy
-
批准号:10242125
-
项目类别:
-
资助金额:$57.49万
-
财政年份:2019
-
负责人:Harris R Perlman
-
依托单位:
Macrophage Modulation of Lung Fibrosis
-
批准号:9264201
-
项目类别:
-
资助金额:$66.72万
-
财政年份:2017
-
负责人:Harris R Perlman
-
依托单位:
RhEumatoid Arthritis SynOvial tissue Network (REASON)
-
批准号:9130014
-
项目类别:
-
资助金额:$14.72万
-
财政年份:2014
-
负责人:Harris R Perlman
-
依托单位:
RhEumatoid Arthritis SynOvial tissue Network (REASON)
-
批准号:9130011
-
项目类别:
-
资助金额:$14.68万
-
财政年份:2014
-
负责人:Harris R Perlman
-
依托单位:
RhEumatoid Arthritis SynOvial tissue Network (REASON)
-
批准号:8851790
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2014
-
负责人:Harris R Perlman
-
依托单位:
Development of a Novel RA/Atherosclerosis Mouse Model
-
批准号:9124741
-
项目类别:
-
资助金额:$32.83万
-
财政年份:2013
-
负责人:Harris R Perlman
-
依托单位:
Development of a Novel RA/Atherosclerosis Mouse Model
-
批准号:8618733
-
项目类别:
-
资助金额:$32.83万
-
财政年份:2013
-
负责人:Harris R Perlman
-
依托单位:
Development of a Novel RA/Atherosclerosis Mouse Model
-
批准号:8897866
-
项目类别:
-
资助金额:$32.83万
-
财政年份:2013
-
负责人:Harris R Perlman
-
依托单位:
Development of a Novel RA/Atherosclerosis Mouse Model
-
批准号:8735615
-
项目类别:
-
资助金额:$32.83万
-
财政年份:2013
-
负责人:Harris R Perlman
-
依托单位:
Development of a Novel RA/Atherosclerosis Mouse Model
-
批准号:9330671
-
项目类别:
-
资助金额:$32.83万
-
财政年份:2013
-
负责人:Harris R Perlman
-
依托单位:
A novel and improved mouse system for studying macrophage specific gene deletion
-
批准号:8038759
-
项目类别:
-
资助金额:$22.88万
-
财政年份:2010
-
负责人:Harris R Perlman
-
依托单位:
A novel and improved mouse system for studying macrophage specific gene deletion
-
批准号:8204742
-
项目类别:
-
资助金额:$19.06万
-
财政年份:2010
-
负责人:Harris R Perlman
-
依托单位:
Role of BH3-Domain Proteins in the Effector Phase of RA
-
批准号:8080888
-
项目类别:
-
资助金额:$31.89万
-
财政年份:2008
-
负责人:Harris R Perlman
-
依托单位:
海外基金